<SEC-DOCUMENT>0001213900-21-018989.txt : 20210331
<SEC-HEADER>0001213900-21-018989.hdr.sgml : 20210331
<ACCEPTANCE-DATETIME>20210331091312
ACCESSION NUMBER:		0001213900-21-018989
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210331
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210331
DATE AS OF CHANGE:		20210331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54716
		FILM NUMBER:		21790188

	BUSINESS ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea138690-8k_neuroone.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C.&nbsp; 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):
<B>March 31, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-54716</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>27-0863354</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer <BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>7599 Anagram Dr., Eden Prairie, MN 55344</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>952-426-1383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s former name or former
address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center; text-indent: 4.15pt"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging Growth Company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both">
<B>Item 3.03. Material Modification to Rights of Security Holders.</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">To the extent required by Item 3.03 of
Form 8-K, the information contained in Item 5.03 of this report is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both">
<B>Item 5.03. Amendment to Articles of Incorporation or Bylaws, Change in Fiscal Year.</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 2, 2020, NeuroOne Medical Technologies
Corporation (the <B><I>&ldquo;Company&rdquo;</I></B>) held a meeting of stockholders (the <B><I>&ldquo;Annual Meeting&rdquo;</I></B>).
At the Annual Meeting, the stockholders approved the proposal to amend the Company&rsquo;s Certificate of Incorporation (the <B><I>&ldquo;Certificate
of Incorporation&rdquo;</I></B> ), to effect a reverse stock split of its outstanding common stock at a ratio in the range of one-for-two
to one-for-five, to be determined at the discretion of the board of directors of the Company (the <B><I>&ldquo;Board&rdquo;</I></B>
).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">On March 11, 2021, the Board approved a
one-for-three reverse stock split of the Company&rsquo;s issued and outstanding shares of common stock (the <B><I>&ldquo;Reverse
Stock Split&rdquo;</I></B>). On March 31, 2021, the Company filed with the Secretary of State of the State of Delaware a Certificate
of Amendment to its Certificate of Incorporation (the <B><I>&ldquo;Certificate of Amendment&rdquo;</I></B>) to effect the Reverse
Stock Split. The Reverse Stock Split will become effective as of 4:01 p.m. Eastern Time on March 31, 2021, and the Company&rsquo;s
common stock will begin trading on a split-adjusted basis when the market opens on April 1, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">When the Reverse Stock Split becomes effective,
every three shares of the Company&rsquo;s issued and outstanding common stock (and such shares held in treasury) will automatically
be converted into one share of common stock, without any change in the par value per share. In addition, a proportionate adjustment
will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options,
restricted stock units and warrants to purchase shares of common stock and the number of shares reserved for issuance pursuant
to the Company&rsquo;s equity incentive compensation plans. Any fraction of a share of common stock that would be created as a
result of the Reverse Stock Split will be rounded up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">The Company&rsquo;s common stock will
continue to trade on the OTCQB under the symbol &ldquo;NMTC.&rdquo; The new CUSIP number for the common stock following the Reverse
Stock Split will be 64130M 209.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">For more information about the Reverse
Stock Split, see the Company&rsquo;s Definitive Proxy Statement on Schedule 14A, which was filed with the Securities and Exchange
Commission and mailed to the Company&rsquo;s stockholders on or about May 1, 2020, the relevant portions of which are incorporated
herein by reference. A copy of the Certificate of Amendment is attached as Exhibit 3.1 hereto and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01. Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 31, 2021, the Company issued a
press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in this&nbsp;Item 7.01,
including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed &ldquo;filed&rdquo; for any purpose, and shall
not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;9.01.</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d)&nbsp; Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="width: 92%"><A HREF="ea138690ex3-1_neuroone.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>99.1</TD>
    <TD><A HREF="ea138690ex99-1_neuroone.htm" STYLE="-sec-extract: exhibit">Press Release dated March 31, 2021 announcing the Reverse Stock Split.</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 62%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Dated: March 31, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ David Rosa</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">David Rosa</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ea138690ex3-1_neuroone.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 3.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Certificate
of Amendment<BR>
<BR>
to the<BR>
<BR>
Certificate of Incorporation of<BR>
<BR>
NeuroOne Medical Technologies Corporation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>NeuroOne
Medical Technologies Corporation</B>,</FONT> a corporation organized and existing under and by virtue of the General Corporation
Law of the State of Delaware (the <B><I>&ldquo;Corporation&rdquo;</I></B>), does hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>First:&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>That
the Board of Directors of the Corporation duly adopted resolutions to amend its Certificate of Incorporation as follows, declaring
this certificate of amendment (the &ldquo;<B><I>Certificate of Amendment</I></B>&rdquo;) to be advisable and calling for submission
of said resolution to a vote of the stockholders of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Second:&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>That
thereafter, at a meeting duly called and held upon notice in accordance with Section 222 of the General Corporation Law of the
State of Delaware, the stockholders of the Corporation duly voted a majority of the outstanding stock of the Corporation entitled
to vote thereon in favor of adoption of this Certificate of Amendment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Third:&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>That
this Certificate of Amendment being duly adopted in accordance with the provisions of Section 242 of the General Corporation Law
of the State of Delaware, the Certificate of Incorporation of NeuroOne Medical Technologies Corporation is hereby amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">Paragraph A of <FONT STYLE="font-variant: small-caps">Article
IV, Authorized Stock and Relative Rights</FONT>, is hereby deleted in its entirety and replaced by the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;The Corporation is authorized
to issue two classes of stock to be designated, respectively, &ldquo;Common Stock&rdquo; and &ldquo;Preferred Stock&rdquo;. The
total number of shares that the Corporation is authorized to issue is 110,000,000 shares. 100,000,000 shares shall be Common Stock
and 10,000,000 shares shall be Preferred Stock, each having a par value of $0.001 per share. Upon the filing and effectiveness
(the <B><I>&ldquo;Effective Time&rdquo;</I></B>) pursuant to the General Corporation Law of the State of Delaware (the <B><I>&ldquo;DGCL&rdquo;</I></B>)
of this Certificate of Amendment to the Certificate of Incorporation of the Corporation, each three (3) shares of the Corporation&rsquo;s
Common Stock issued and outstanding immediately prior to the Effective Time shall, automatically and without any action on the
part of the Corporation or respective holders thereof, be combined and converted into one (1) validly issued, fully paid and non-assessable
share of Common Stock of the Corporation (the <B><I>&ldquo;Reverse Split&rdquo;</I></B>). No fractional shares of Common Stock
shall be issued in connection with the Reverse Split. In lieu thereof, any fractional share that results from the combination described
in the two immediately preceding sentences will be rounded up to the next whole share of Common Stock.&rdquo;; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Fourth</B></FONT>:
That this Certificate of Amendment shall become effective as of 4:01 p.m., Eastern Time on March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B></FONT>, the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer
this 31<SUP>st</SUP> day of March, 2021.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 47%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 52%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>NeuroOne Medical Technologies
        Corporation</B></FONT>,<BR>
        <BR>
        a&nbsp;Delaware corporation</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 53%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 91%">/s/ David Rosa</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>David Rosa</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
</TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; background-color: white; text-indent: 225pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ea138690ex99-1_neuroone.htm
<DESCRIPTION>PRESS RELEASE DATED MARCH 31, 2021 ANNOUNCING THE REVERSE STOCK SPLIT.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 39pt; width: 206.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-size: 11pt"><B>NeuroOne
Medical Technologies Corporation Announces Reverse Stock Split as Part of Uplisting Strategy to Major Exchange</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Eden Prairie, MN &ndash; March 31, 2021&ndash; </B><U>NeuroOne
Medical Technologies Corporation</U> (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving
surgical care options and outcomes for patients suffering from neurological disorders, announces today a reverse stock split of
its issued and outstanding common stock, at a ratio of 1-for-3, effective at 4:01 pm Eastern time today. Beginning tomorrow, April
1, 2021, NeuroOne&rsquo;s common stock will trade on a split-adjusted basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dave Rosa, CEO of NeuroOne Medical Technologies Corporation
says, &ldquo;As part of our corporate strategy to uplist to a major exchange, we are excited to take the next step in this process.
In addition to our existing shareholder base, we are grateful to our new institutional investors that have provided important growth
capital to launch new products and uplist the company. We look forward to updating the market on our future progress as we move
forward with a major national exchange.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon effectiveness, the reverse split will cause every 3 shares
of NeuroOne&rsquo;s issued and outstanding common stock to be automatically combined and converted into 1 issued and outstanding
share of common stock, par value $0.001 per share. The reverse stock split will reduce the number of shares of common stock issuable
upon the exercise or vesting of its outstanding stock options, restricted stock units and warrants in proportion to the ratio of
the reverse stock split and causes a proportionate increase in the exercise prices of such stock options and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NeuroOne&rsquo;s common stock will continue to trade on the
OTCQB under the symbol &ldquo;NMTC.&rdquo; The new CUSIP number for the common stock following the reverse split is 64130M 209.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About NeuroOne</B><BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition
solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease,
dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve
patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 23, 2021, </FONT>the Company <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announced it had
successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July
20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne&rsquo;s Evo&trade; (Evo) patented electrode
technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were
met within a specified time frame. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">NeuroOne received FDA
clearance for its Evo cortical technology in November 2019. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">In partnership with Mayo
Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing
its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring
markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&rsquo;s disease,
epilepsy and pain management due to failed back surgery procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward Looking Statements</B><BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained
in this presentation may be a forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking statement that reflects
NeuroOne&rsquo;s current views about future events and are subject to known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some cases, you can identify forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking
statements by the words &quot;may,&quot; &quot;might,&quot; &quot;will,&quot; &quot;could,&quot; &quot;would,&quot; &quot;should,&quot;
&quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;objective,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot;
&quot;predict,&quot; &quot;project,&quot; &quot;potential,&quot; &quot;target,&quot; &quot;seek,&quot; &quot;contemplate,&quot;
&quot;continue&quot; and &quot;ongoing,&quot; or the negative of these terms, or other comparable terminology intended to identify
statements about the future. Forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking statements may include
statements regarding the potential uplisting on the Nasdaq Stock Market, the timing of submission of our second 510(k) application,
the receipt of regulatory clearance, the timing and extent of product launch and commercialization of the technology (including
the targeted product launch in 2021), what the future may hold for electrical stimulation and NeuroOne&rsquo;s potential role,
business strategy, market size, potential growth opportunities, plans for product applications and product development, future
operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable
basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors
currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially
different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet
may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready
for commercialization in a timely manner or at all; risks that our technology will not perform as expected based on results of
our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development process
of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of
the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our intellectual
property rights and other risks, uncertainties and assumptions, including those described under the heading &quot;Risk Factors&quot;
in our filings with the Securities and Exchange Commission. These forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking
statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking
statements for any reason, even if new information becomes available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investor Relations Contact</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Kelly Novak</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Perspective Communications<BR>
kellyn@n1mtc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&quot;Caution: Federal law restricts
this device to sale by or on the order of a physician&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>SOURCE:&nbsp;</B>NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D A,# 2(  A$! Q$!_\0
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M@ HHHH **X_Q=XQN/#FH06T-I%,)(O,)=B,<D=OI3?"7C2X\1ZK+9S6D4*I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0L['Y5S\J#LH'84AG6ZI\3=0G=DTVWCMHNSR#>Y_H/UK!?QEXAD8L=5F!/\
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M1; @CW*D\_@?PK@M9\):YH""34=/DBA)QYJD.F?J"0/QK%J98?#UHW27JO\
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M(S^%-IZ)<.H^G!_K3$=+J%Y]@L9+GRS($QE0<=2!_6L/_A,(_P#GS;_OY_\
M6K=U"W-UIUQ !DNA ^O;]:\WK&I)IZ'J8&A2K1?.M4=7_P )A'_SYM_W\_\
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M%-25UL=7IOBE"@BOP0PX\U1D'ZC_  KH+>[M[M2;>>.3'7:V2/K7FE=-X/\
M]==_[J_UK6$VW9GEXS!TXP=2.AI:KXKT+12ZW^IV\<J=8E;=(/\ @(R:\H\9
M?$RXUR&33]+1[6Q?B1V/[R4>G'W1[=_TK%^(?_(^ZK_UT7_T!:YBOI,+@J<4
MJCU>Y\?B<74DW!:(***Z/P?X2NO%6JB)0T=E$0;B?'W1Z#_:/;\Z[ISC"+E+
M9''"+G)1CN=M\(/#K+]HU^X3 (,-MD=?[S#^7YUZQ4%G:06%G#:6L:QP0H$1
M%Z "IZ^9Q%9UJCFSZ"A25*"BCYD\4_\ (W:U_P!?\_\ Z,:LFM;Q3_R-VM?]
M?\__ *,:LFOI:?P+T7Y(^?G\;]7^9ZS\%/\ F.?]N_\ [4KUBO)_@I_S'/\
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M7)->RQ> O#<3;OL!<]M\SD?EFMNST^ST^/R[.UA@3N(T"Y^N.M CC?"'@/\
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M5W[VW8[J.'A17N[A1117.;GS)XI_Y&[6O^O^?_T8U9-?6-%>M'-.6*7+^/\
MP#S99==M\WX'D_P4_P"8Y_V[_P#M2O6***\^O5]K4<[6N=M&G[*"A>]CD_B9
M_P D^U3_ +9?^C4KYZKZQHKHPN-]A!QY;F&(PGMI<U['R=7U!H'_ "+FE_\
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L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
